2023 Midwest Radiation Oncology Symposium (Attendee Information)

Fred & Pamela Buffett Cancer Center – Rm 0.12.103 (NEW LOCATION!)
505 S 45th Street, Omaha, NE 68105

Parking

• Complimentary parking for campus visitors is available on the top level of Lot 50. Download map
• If you are an employee/student of UNMC/Nebraska Medicine, please park in your regularly assigned parking area.
• UNMC CCE is not liable for any parking ticket that a participant may incur when attending this symposium.

• The Zoom link for the live stream will be sent via email a few days prior to the symposium. If you do not see this email in your Inbox, please check your junk email folder. If you still do not see the message, please send an email to Brenda Ram.
• To join the symposium, sign in to Zoom using your first and last name.
• Once you are in the webinar, go to the chat box and type in your first and last name so your attendance may be recorded.

Read the UNMC CCE Disclosure Declaration Policy 

Disclosures

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

FACULTY

The following have disclosed relevant financial relationships:

Christopher R. D'Angelo, MD

• Advisory Board: Bristol-Myers Squibb Company; Ono Pharmaceutical Co., Ltd.; Seagen Inc.
• Consultant: AbbVie, Inc.
• Researcher: AbbVie, Inc.; Beigene; Bristol-Myers Squibb Company; Fate Therapeutics

Megan Hyun, PhD, DABR*

• Researcher: Standard Imaging, Inc.
• Speaker: Radformation, Inc; Varian Medical Systems, Inc.

Sidharth Mahapatra, MD, PhD

• Grant Reviewer: American Institute of Biological Sciences; Cariplo Foundation, Italy; New Jersey Department of Health

• Research funding: Edna Ittner Pediatric Research Fund; FPBCC/PCRG Pilot Project Grant; Team Jack Foundation

• INVESTIGATIONAL/OFF-LABEL USE OF DRUGS DISCLOSURE:  Nortriptylline, Simvastatin, Fluoxetine, Sertraline for Anti-neoplastic effects in group 3 medulloblastoma

Jessica Maxwell, MD, MSc

• Advisor: Dilon Technologies, Inc.

Benjamin A. Teply, MD

• Advisory Board: Exelixis, Inc.; Lilly; Sanofi; Seagen Inc.
• Consultant: ONVIV/Cancer Expert Now
• INVESTIGATIONAL/OFF-LABEL USE OF DRUGS DISCLOSURE: Off-label drug discussion of Immunotherapy (Pembrolizumab/Nivolumab) in muscle-invasive bladder cancer

Chi (Kevin) Zhang, MD, PhD*

• Research Grant: AstraZeneca
• Travel Support: GT Medical Technologies, Inc.

The following have nothing to disclose:

• Omar K. M. Abughanimeh, MBBS
• Ellie Bacon, MS
• Michael Baine, MD, PhD
• Christopher M. Bingcang, MD
• Charles A. Enke, MD, FASTRO, FACR*
• Eric Ford, PhD, DABR, FAAPM, FASTRO
• Kyle J. Gallagher, PhD, DABR
• Samuel Hendley, PhD
• Miki Katzir, MD
• Mridula Krishnan, MBBS
• Sean Langenfield, MD, FACS, FASCRS
• Chi Lin, MD, PhD*
• Jeff M. Michalski, MD, MBA, FASTRO
• Kyuhak Oh, PhD
• Jared P. Schober, MD
• Diane Schott, PhD
• Andrew Wahl, MD
• Sarah Wisnoskie, MS
• Shannon L. Wong, MD
• Ying Yan, PhD
• Weining (Ken) Zhen, MD, FACR, FASTRO
• Su-min Zhou, PhD

 *Faculty and planning committee member

PLANNING COMMITTEE

The following have nothing to disclose:

• Heidi Keeler, PhD, MSN/MBA, RN
• Renee Paulin, MSN, RN, CWOCN
• Brenda Ram, CMP, CHCP
• Hongmei Ren, RN
• Charlene Rhodd, MS, CMD, RT (R)(T), CT 

• Courtney Smith
• Ann L. Yager, MHA, BS, RT, (R)(T)